Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels.
Danese
S
S
Papa
A
A
Gasbarrini
G
G
Gasbarrini
A
A
D001528:Behcet Syndrome / Q000097:blood* / Q000150:complications / Q000235:genetics; D005492:Folic Acid / Q000097:blood; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood* / Q000209:etiology / Q000235:genetics; D014805:Vitamin B 12 / Q000097:blood; D025101:Vitamin B 6 / Q000097:blood
D006710:Homocysteine; D025101:Vitamin B 6; D005492:Folic Acid; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D014805:Vitamin B 12